STF-31 (CAS: 724741-75-7)

C₂₃H₂₅N₃O₃S

• Specific nicotinamide phosphoribosyltransferase (NAMPT) inhibitor (IC₅₀=19nM), consequently blocking the NAD⁺ salvage pathway and leading to blockage of GLUT1 expression.
• Glucose transporter 1 (GLUT1) inhibitor (IC₅₀ ~1µM). Inhibits glucose uptake across the plasma membranes of mammalian cells and consequently decreases glycolysis.
• Anticancer agent. Shown to induce necrosis in cancer cells that lack the von Hippel-Lindau (VHL) tumor suppressor gene, which overexpresses GLUT1. VHL-deficient cancer cells are dependent on the high affinity GLUT1 transporter and aerobic glycolysis for ATP production. Completely suppresses the glucose uptake activity and induces apoptosis in GLUT1 expressing myeloma cells as well.
• Useful agent for immunometabolism research.
• Toxic to human pluripotent stem cells (hPSCs) and used to selectively eliminate hPSCs from mixed cultures.

1. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality: D.A. Chan, et al.; Sci. Transl. Med. 3, 94ra70 (2011)
2. NAMPT is the cellular target of STF-31-like small-molecule probes: D.J. Adams, et al.; ACS Chem. Biol. 9, 2247 (2014)
3. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphribosyltransferase (NAMPT): P.S. Dragovich, et al.; Bioorg. Med. Chem. Lett. 24, 954 (2014)
4. A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets: K.R. Boheler, et al.; Stem Cell Reports 3, 185 (2014)
5. Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells: E.M. Kropp, et al.; Stem Cells Transl. Med. 4, 483 (2015)
6. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models: C. Xintaropoulou, et al.; Oncotarget 6, 25677 (2015) (Review)
7. Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells: A. Nomura, et al.; Oncotarget 7, 56324 (2016)
8. A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016) (Review)
9. Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents: T. Matsumoto, et al.; Leuk. Res. 41, 103 (2016)
10. Dynamic Profiling of Insulin Secretion and ATP Generation in Isolated Human and Mouse Islets Reveals Differential Glucose Sensitivity: A. Pingitore, et al.; Cell Physiol. Biochem. 44, 1352 (2017)